CN100341568C - 改变化学治疗剂的活性的丁酰胆碱酯酶变体 - Google Patents

改变化学治疗剂的活性的丁酰胆碱酯酶变体 Download PDF

Info

Publication number
CN100341568C
CN100341568C CNB2003801050807A CN200380105080A CN100341568C CN 100341568 C CN100341568 C CN 100341568C CN B2003801050807 A CNB2003801050807 A CN B2003801050807A CN 200380105080 A CN200380105080 A CN 200380105080A CN 100341568 C CN100341568 C CN 100341568C
Authority
CN
China
Prior art keywords
butyrylcholinesterase
leu
gly
ser
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801050807A
Other languages
English (en)
Chinese (zh)
Other versions
CN1720063A (zh
Inventor
J·D·沃特金斯
J·D·潘库克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution Inc filed Critical Applied Molecular Evolution Inc
Publication of CN1720063A publication Critical patent/CN1720063A/zh
Application granted granted Critical
Publication of CN100341568C publication Critical patent/CN100341568C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB2003801050807A 2002-12-04 2003-12-04 改变化学治疗剂的活性的丁酰胆碱酯酶变体 Expired - Fee Related CN100341568C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31066602A 2002-12-04 2002-12-04
US10/310,666 2002-12-04

Publications (2)

Publication Number Publication Date
CN1720063A CN1720063A (zh) 2006-01-11
CN100341568C true CN100341568C (zh) 2007-10-10

Family

ID=32468084

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801050807A Expired - Fee Related CN100341568C (zh) 2002-12-04 2003-12-04 改变化学治疗剂的活性的丁酰胆碱酯酶变体

Country Status (9)

Country Link
US (1) US20080213281A1 (enExample)
EP (1) EP1581253A4 (enExample)
JP (1) JP2006508665A (enExample)
CN (1) CN100341568C (enExample)
AU (1) AU2003298920A1 (enExample)
BR (1) BR0316865A (enExample)
CA (1) CA2507626A1 (enExample)
MX (1) MXPA05005996A (enExample)
WO (1) WO2004050041A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP2049661A4 (en) * 2006-08-04 2012-07-04 Pharmathene Inc RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
KR20110008075A (ko) * 2008-05-16 2011-01-25 넥타르 테라퓨틱스 콜린에스테라아제 부분 및 폴리머의 콘쥬게이트
WO2011084145A2 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
CN103898101B (zh) * 2012-12-27 2017-08-08 上海桀蒙生物技术有限公司 利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法
CN104630177A (zh) * 2013-11-08 2015-05-20 中国农业大学 一种利用人丁酰胆碱酯酶迷你基因在乳腺中表达重组人丁酰胆碱脂酶的方法
EP3137098A4 (en) 2014-04-29 2017-11-01 Mayo Foundation for Medical Education and Research Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
WO2018053216A1 (en) * 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
WO1999066072A2 (en) * 1998-06-16 1999-12-23 Nova Molecular, Inc. Methods for treating a neurological disease by determining bche genotype
CN1331339A (zh) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸
WO2002064796A2 (en) * 2000-12-26 2002-08-22 Applied Molecular Evolution, Inc. Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633318A1 (en) * 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5506125A (en) * 1993-12-22 1996-04-09 Agracetus, Inc. Gene delivery instrument with replaceable cartridges
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US20030153062A1 (en) * 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7070973B2 (en) * 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
US7049121B2 (en) * 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
WO1999066072A2 (en) * 1998-06-16 1999-12-23 Nova Molecular, Inc. Methods for treating a neurological disease by determining bche genotype
CN1331339A (zh) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸
WO2002064796A2 (en) * 2000-12-26 2002-08-22 Applied Molecular Evolution, Inc. Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The anticancer prodrug CPT-11 is a potent inhibitor ofacetylcholinesterase but is rapidly catalyzed to SN-38 bybutyrylcholinesterase Christopher L. Morton,et al.,Cancer research,No.59 1999 *

Also Published As

Publication number Publication date
BR0316865A (pt) 2005-10-25
CA2507626A1 (en) 2004-06-17
MXPA05005996A (es) 2006-04-18
EP1581253A2 (en) 2005-10-05
AU2003298920A1 (en) 2004-06-23
CN1720063A (zh) 2006-01-11
WO2004050041A3 (en) 2004-10-28
US20080213281A1 (en) 2008-09-04
JP2006508665A (ja) 2006-03-16
WO2004050041A2 (en) 2004-06-17
EP1581253A4 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
CN1246462C (zh) 修饰的维生素k依赖性多肽
CN100341568C (zh) 改变化学治疗剂的活性的丁酰胆碱酯酶变体
CN1153830C (zh) 锚定蛋白功能的调节剂
CN1229499C (zh) 磷酸二酯酶8a
CN1596313A (zh) 人源化的胶原抗体及相关方法
JP2009537140A (ja) ジヒドロ葉酸還元酵素の不活性化のための方法及び組成物
CN1390232A (zh) 人β分泌酶、抑制剂、其组合物和用途
CN1313773A (zh) 来自端粒酶的抗原性肽
CN1537167A (zh) 酶切范威尔邦德因子(vWF)的蛋白酶
CN1774243A (zh) 治疗组合物
CN1091139A (zh) 蛋白质酪氨酸磷酸酶的ptp-d亚家族
CN1768142A (zh) 嵌合多肽及其用途
CN1409722A (zh) BMP和TGFβ信号转导途径的拮抗剂
CN1167793C (zh) 人脂酶样基因编码的多肽及利用它的组合物和方法
CN1232498A (zh) Rho gtp酶鸟嘌呤交换因子和编码该因子的核酸
WO2007058381A1 (ja) 基質特異性を変換した新規高機能酵素
CN1897951A (zh) h－PRUNE的酶抑制剂在过度表达h－PRUNE的肿瘤转移的预防和治疗中的应用
CN1739788A (zh) Trip－br功能的调节和治疗增殖性紊乱的方法
CN1286973C (zh) 一种组蛋白甲基转移酶及其制备方法
CN1909927A (zh) 抑制癌的方法
CN101035554A (zh) 介导应激反应的肽抑制剂
CN1875100A (zh) BACE455,人β－分泌酶的可变剪接变体
CN1201009C (zh) 组氨酸蛋白磷酸酶
CN1436239A (zh) 新酶基因及其表达产物
CN1289524C (zh) 一种人端粒酶活性抑制蛋白及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee